#USA #New York #Gross Law Firm #Rocket Pharmaceuticals #RCKT

Class Action Filed Against Rocket Pharmaceuticals, Inc.

On August 11, 2025, news broke that The Gross Law Firm initiated a class-action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). This legal action aims to address claims of significant misstatements and omissions that may have misled investors. The lawsuit is particularly focused on the period from September 17, 2024, to May 26, 2025, a time frame during which shareholders are being encouraged to register.

Allegations of Misleading Conduct

The Gross Law Firm reports that the suit stems from allegations that Rocket Pharmaceuticals made highly positive claims about its clinical programs while failing to disclose serious risks associated with RP-A501, a treatment undergoing trials at the time. The core of the complaint revolves around the failure to inform investors about Serious Adverse Events (SAEs), including the death of a participant involved in the clinical study. This key omission allegedly misled investors into believing that the company was operating under normal circumstances, causing them to purchase shares at inflated prices.

According to the suit, Rocket Pharmaceuticals did amend its clinical trial protocol to introduce a new immunomodulatory agent but neglected to communicate this crucial change to shareholders in a timely manner. Such actions can be characterized as a breach of fiduciary duty, further aggravating the frustration among investors who relied on the company's assurances while pricing climbed.

Fallout from FDA's Clinical Hold

The situation took a dire turn when, on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) had placed a clinical hold on the RP-A501 Phase 2 pivotal study. This came shortly after one of the trial participants suffered a Serious Adverse Event that led to their death. Rocket disclosed that while the patient was dosed in May, the decision to amend the protocol had been made several months earlier. However, shareholders had not been warned about this revision until the SAE incident.

As a result of these revelations, Rocket's stock price plummeted. The company’s shares, which closed at $6.27 on May 23, 2025, dropped to $2.33 by May 27, marking a staggering decline of about 37% in just a day. This dramatic fall is prompting many investors to reassess their options regarding their financial decisions relating to Rocket Pharmaceuticals.

Important Deadlines for Shareholders

Shareholders that purchased RCKT shares within the specified class period are urged to act quickly. The deadline to register for participation in the class action is set for August 11, 2025. Interested parties can complete their registration online through the dedicated site managed by The Gross Law Firm. Once enrolled, shareholders will have access to monitoring software that will keep them updated on the case's developments.

Additionally, potential lead plaintiffs may have the opportunity to represent the shareholders' interests more vigorously; however, being appointed as a lead plaintiff is not a requirement to benefit from any recovery.

Why Choose The Gross Law Firm?

The Gross Law Firm is highly regarded nationally for its commitment to protecting investors' rights, particularly in cases of deceitful practices or misleading information from companies. Their mission emphasizes the importance of responsible corporate behavior and seeks to recover losses incurred by investors due to misrepresentation. Participation in this case bears no cost for shareholders, and the firm operates on a contingency basis, ensuring that they only receive payment if recovery is achieved.

For any inquiries, shareholders can reach The Gross Law Firm via their contact details provided. As the legal process progresses, the firm aims to keep all affected investors informed and supported throughout this challenging period.

Investors are reminded that taking prompt action can make a difference in the outcomes associated with this lawsuit.